Multi-Layer Tablet with Barrier for Cetirizine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Combining antihistamine cetirizine, nasal decongestant pseudoephedrine, and analgesic naproxen into a single tablet is challenging due to differences in duration of action and incompatibility, with pseudoephedrine not being approved for extended release and cetirizine degrading in the presence of both pseudoephedrine and naproxen.
Innovation Solution
A tablet design featuring a first drug layer with naproxen, a sustained release second layer with pseudoephedrine for at least four hours, a barrier layer not containing naproxen, and a third layer with cetirizine, manufactured through granulation and compression processes to prevent degradation and ensure extended release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If cetirizine, pseudoephedrine, and naproxen are combined in a single tablet, then all three symptoms (allergy, congestion, headache) can be treated simultaneously, but cetirizine degrades due to physical presence of pseudoephedrine and naproxen
Solution Approach 1:
The tablet is divided into distinct layers: a first layer containing naproxen and pseudoephedrine, and a second layer containing cetirizine. This segmentation physically separates incompatible substances to prevent degradation while maintaining simultaneous treatment of multiple symptoms in a single tablet.
Solution Approach 2:
A barrier layer is introduced between the first layer (naproxen and pseudoephedrine) and the second layer (cetirizine). This intermediary barrier prevents direct contact and chemical interaction between incompatible substances, protecting cetirizine from degradation while allowing all three drugs to coexist in a single tablet.
2Duration of action of moving object
If pseudoephedrine is extended release to maintain therapeutic levels for 8+ hours, then duration of action is improved, but pseudoephedrine is not approved for extended release formulation
Solution Approach 1:
The tablet provides different release characteristics to different drugs: pseudoephedrine is formulated in a sustained-release layer for extended delivery, while cetirizine and naproxen are in immediate-release layers. This local differentiation of release properties allows pseudoephedrine to achieve the required 8+ hour duration without requiring approval for extended-release formulation of the entire tablet.
Solution Approach 2:
The tablet is segmented into layers with different release profiles. The first layer contains sustained-release pseudoephedrine designed for extended delivery, while the second layer contains immediate-release cetirizine. This segmentation allows each drug to have its optimal release characteristics without compromising regulatory approval.
3Ease of manufacture
If all three drugs are combined in immediate release form, then manufacturing is simpler, but the duration of action is insufficient for 8+ hours coverage
Solution Approach 1:
The tablet is divided into layers with different release mechanisms. The first layer uses sustained-release technology for pseudoephedrine to extend duration, while the second layer uses immediate-release for cetirizine. This segmentation achieves extended duration of action while maintaining relatively simple manufacturing through a layered compression process.
Data Source
AI summary
In one aspect, the present invention features a tablet including: (i) a first drug layer including naproxen; (ii) a second drug layer including a decongestant (e.g., pseudoephedrine) wherein said second drug layer is a sustained release layer adapted to deliver a therapeutically effective amount of pseudoephedrine for a period of at least twelve hours; and (iii) a barrier layer that does not include naproxen, wherein the barrier layer is in contact with the first drug layer; and (iv) a third drug layer including cetirizine, wherein the third drug layer is in contact with the barrier layer and is not in contact with the first drug layer.